Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autoimmune disease

- PMLiVE

EMA and HMAs publish workplan to guide use of AI in medicines regulation

The document aims to maximise the benefits and mitigate the risks of AI in medicine

- PMLiVE

Merck and Owkin collaborate to develop AI-powered diagnostics for cancer

The companies aim to develop a pre-screening test to improve MSI-H testing for cancer

- PMLiVE

Sanofi and AI specialist Aqemia enter $140m drug discovery partnership

The deal is aimed at discovering small molecule drugs across several therapeutic areas

- PMLiVE

Almirall, BSC and Nostrum Biodiscovery partner for dermatological diseases

The collaboration will aim to find new therapies for dermatological diseases through AI

- PMLiVE

AstraZeneca and generative AI company Absci enter $247m oncology partnership

The collaboration is aimed at developing an AI-designed antibody drug for an oncology target

- PMLiVE

Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership

The collaboration will see Boehringer use an IBM-developed AI model to boost its drug discovery efforts

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

About 300,000 people in the US have uncontrolled COPD and type 2 inflammation

Can Cinderella save us?

Study finds AI detects AMR faster than gold-standard testing

The method detected AMR with at least 80% accuracy on a per-cell basis, within 30 minutes

- PMLiVE

Healthcare in the age of AI: How will artificial intelligence impact future decision-making?

Authored by: Constanza Salas, Jhon Galindo and Rachel Howard

Research Partnership

- PMLiVE

AstraZeneca announces launch of new healthtech business Evinova to optimise clinical trials

Evinova aims to meet the needs of patients, healthcare professionals and regulators

- PMLiVE

Almirall and Absci announce $650m AI dermatological drug discovery partnership

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology

- PMLiVE

AstraZeneca and Cellectis enter gene therapy partnership worth over $2.2bn

The deal gives AZ access to Cellectis’ gene editing technologies and manufacturing capabilities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links